344 related articles for article (PubMed ID: 30362375)
21. Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients.
Aviles P; Altares R; van Andel L; Lubomirov R; Fudio S; Rosing H; Márquez Del Pino FM; Tibben MM; Benedit G; Nan-Offeringa L; Luepke Estefan XE; Francesch A; Zeaiter A; Cuevas C; Schellens JHM; Beijnen JH
Drug Metab Dispos; 2022 Apr; 50(4):327-340. PubMed ID: 35042701
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V; Paz-Ares L; Besse B; Moreno V; Peters S; Sala MA; López-Vilariño JA; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Zaman K; López R; Ponce S; Boni V; Arrondeau J; Delord JP; Martínez M; Wannesson L; Antón A; Valdivia J; Awada A; Kristeleit R; Olmedo ME; Rubio MJ; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D' Arcangelo M; Santoro A; Villalobos VM; Sands J; Trigo J
Lung Cancer; 2020 Dec; 150():90-96. PubMed ID: 33096421
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy.
Scagliotti G; Nishio M; Satouchi M; Valmadre G; Niho S; Galetta D; Cortinovis D; Benedetti F; Yoshihara E; Makris L; Inoue A; Kubota K
Lung Cancer; 2016 Oct; 100():20-23. PubMed ID: 27597276
[TBL] [Abstract][Full Text] [Related]
24. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
25. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
26. Lurbinectedin: First Approval.
Markham A
Drugs; 2020 Sep; 80(13):1345-1353. PubMed ID: 32816202
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
[TBL] [Abstract][Full Text] [Related]
28. Lurbinectedin: A New Treatment Option for Relapsed/Refractory Small-Cell Lung Cancer.
Shinn LT; Vo KA; Reeves DJ
Ann Pharmacother; 2021 Sep; 55(9):1172-1179. PubMed ID: 33348988
[TBL] [Abstract][Full Text] [Related]
29. Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.
Risnik D; Colado A; Podaza E; Almejún MB; Elías EE; Bezares RF; Fernández-Grecco H; Seija N; Oppezzo P; Borge M; Gamberale R; Giordano M
Cancer Immunol Immunother; 2020 May; 69(5):813-824. PubMed ID: 32055920
[TBL] [Abstract][Full Text] [Related]
30. Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.
Mascarenhas L; Felgenhauer JL; Bond MC; Villaluna D; Femino JD; Laack NN; Ranganathan S; Meyer J; Womer RB; Gorlick R; Krailo MD; Marina N
Pediatr Blood Cancer; 2016 Mar; 63(3):493-8. PubMed ID: 26579879
[TBL] [Abstract][Full Text] [Related]
31. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
Johnson DH; Einhorn LH; Birch R; Vollmer R; Perez C; Krauss S; Omura G; Greco FA
J Clin Oncol; 1987 Nov; 5(11):1731-8. PubMed ID: 2824707
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.
Garassino MC; Torri V; Michetti G; Lo Dico M; La Verde N; Aglione S; Mancuso A; Gallerani E; Galetta D; Martelli O; Collovà E; Fatigoni S; Ghidini A; Saggia C; Bareggi C; Rossi A; Farina G; Thatcher N; Blackhall F; Lorigan P; Califano R
Lung Cancer; 2011 Jun; 72(3):378-83. PubMed ID: 20950888
[TBL] [Abstract][Full Text] [Related]
34. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
Belgiovine C; Bello E; Liguori M; Craparotta I; Mannarino L; Paracchini L; Beltrame L; Marchini S; Galmarini CM; Mantovani A; Frapolli R; Allavena P; D'Incalci M
Br J Cancer; 2017 Aug; 117(5):628-638. PubMed ID: 28683469
[TBL] [Abstract][Full Text] [Related]
35. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
[TBL] [Abstract][Full Text] [Related]
36. Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer.
Kepp O; Zitvogel L; Kroemer G
Oncoimmunology; 2020 Jul; 9(1):1795995. PubMed ID: 32923159
[TBL] [Abstract][Full Text] [Related]
37. Current standards of care in small-cell and non-small-cell lung cancer.
Schiller JH
Oncology; 2001; 61 Suppl 1():3-13. PubMed ID: 11598409
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
39. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
40. Therapy of small cell lung cancer with emphasis on oral topotecan.
Pirker R; Berzinec P; Brincat S; Kasan P; Ostoros G; Pesek M; Plāte S; Purkalne G; Rooneem R; Skricková J; Stanculeanu D; Timcheva C; Tzekova V; Zakotnik B; Zielinski CC; Zwitter M
Lung Cancer; 2010 Oct; 70(1):7-13. PubMed ID: 20576312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]